z-logo
open-access-imgOpen Access
Shengyang Yiwei Decoction for the treatment of chronic gastritis
Author(s) -
Momiao Xiong,
Huan Luo,
Wenyu Zhu,
Tao Shen
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000022869
Subject(s) - medicine , chronic gastritis , helicobacter pylori , gastritis , traditional chinese medicine , cochrane library , quality of life (healthcare) , disease , randomized controlled trial , meta analysis , antibiotics , gastroenterology , clinical trial , alternative medicine , pathology , nursing , microbiology and biotechnology , biology
Background: Chronic gastritis is a very common chronic gastric mucosal inflammatory disease in China. Long-term chronic inflammation will aggravate the disease and develop towards gastric cancer. Clinically, infection with Helicobacter pylori ( H pylori) is a common cause. The application of antibiotics to eradicate H pylori has been reported to have produced drug resistance. However, the application of Shengyang Yiwei Decoction(SYD) in traditional Chinese medicine has resulted in significant clinical effects and small side effects. It is used for the treatment of chronic gastritis and other diseases, but there is a lack of systematic reviews on the treatment of chronic gastritis by SYD. This article reviews the efficacy and safety of SYD in the treatment of chronic gastritis. Methods: The registration date for the randomized controlled trials is set by the database to October 15, 2020. Through searching the following 8 Chinese and English electronic databases: Cochrane Library, Embase, PubMed, Science Net, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Chinese Science Journal Database and Wanfang Database to analyze. The main results were clinical efficacy, H pylori infection clearance rate, symptom score and quality of life, and 1-year recurrence rate. Finally, Stata 15 was used for meta-analysis. Results: This study will provide the latest evidence for the treatment of chronic gastritis by SYD in the following aspects: clinical efficacy, H pylori infection clearance rate, quality of life, symptom score, and 1-year recurrence rate. Conclusion: The results of this study will provide evidence for evaluating the effectiveness of SYD in chronic gastritis treatment. OSF registration number: DOI 10.17605/OSF.IO/AZKUQ

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here